Virtu Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Virtu Financial’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11,978	Closed	-$191K	–	1395
2024 Q1	$191K	Buy	+11,978	New	+$180K	0.01%	802
2022 Q4	–	Sell	-88,892	Closed	-$1.14M	–	1700
2022 Q3	$1.14M	Buy	+88,892	New	+$1.05M	0.1%	171
2021 Q3	–	Sell	-13,295	Closed	-$76K	–	1572
2021 Q2	$76K	Buy	+13,295	New	+$68.6K	0.01%	1262
2020 Q4	–	Sell	-62,022	Closed	-$184K	–	1488
2020 Q3	$184K	Buy	+62,022	New	+$243K	0.03%	604
2019 Q4	$40K	Buy	+10,725	New	+$50.2K	﹤0.01%	1235
2019 Q2	–	Sell	-112,568	Closed	-$574K	–	1505
2019 Q1	$574K	Buy	112,568 +8,062	+8%	+$23.7K	0.03%	500
2018 Q4	$201K	Buy	+104,506	New	+$299K	0.01%	960
2018 Q1	–	Sell	-16,764	Closed	-$66K	–	2039
2017 Q4	$66K	Sell	16,764 -13,608	-45%	-$45K	﹤0.01%	2020
2017 Q3	$77K	Buy	+30,372	New	+$83.3K	﹤0.01%	2134

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Virtu Financial's CPRX Position: Q2 2024 in Review

Virtu Financial sold out of Catalyst Pharmaceutical (CPRX) in Q2 2024, closing a stake of 11,978 shares — an estimated $191K sold.

Virtu Financial first reported a position in CPRX in Q3 2017 and held it in 9 quarters. The position peaked at $1.14M in Q3 2022. 271 funds tracked by Wall St. Rank hold CPRX as of Q2 2024.

Virtu Financial reported no remaining Catalyst Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Virtu Financial sold 11,978 Catalyst Pharmaceutical shares in Q2 2024, an estimated $191K.
Virtu Financial first reported a position in Catalyst Pharmaceutical in Q3 2017 and held it in 9 quarters.
Virtu Financial's Catalyst Pharmaceutical position peaked at $1.14M in Q3 2022.
271 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2024.

Based on Virtu Financial's 13F filing for Q2 2024, filed 9 Aug 2024.